Colorectal liver metastases
Conditions
Interventions
Trade Name: Oxaliplatin
Product Name: Oxaliplatin
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: OXALIPLATIN
CAS Number: 61825-94-3
Concentration unit: mg/m2 milligram
Sponsors
Erasmus MC Cancer Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Age = 18 years. • ECOG performance status 0 or 1. • Histologically confirmed primary colorectal carcinoma. Primary colorectal carcinomas to be included are: 1. Previously resected histologically proven colorectal carcinoma 2. Coloncarcinoma still in situ, deemed suitable for resection at the time of liver surgery 3. Rectal carcinoma still in situ, requiring no neo-adjuvant radiotherapy, deemed suitable for resection at the time of liver surgery 4. Rectal carcinoma still in situ, requiring short-course neo-adjuvant radiotherapy, deemed suitable for resection at the time of liver surgery • Radiologically confirmed and resectable liver metastasis of colorectal cancer after surgery. • Clinical risk score of 3-5 (Fong et al.). • Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 15 days prior to randomization. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 45 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 179
Exclusion criteria
Exclusion criteria: • Prior adjuvant chemotherapy for the primary colorectal carcinoma given <6 months prior to detection of the liver metastases. • Prior non colorectal malignancies, except for patients with basal or squamous cell carcinoma of the skin, or patients with carcinoma in situ of the cervix. • Presence of extrahepatic disease • Locally advanced rectal cancer in situ requiring long-course pre-operative chemoradiotherapy • Major surgical procedure < 4 weeks prior to randomization. • Females with a positive pregnancy test (within 14 days before treatment start). • History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for oral drug intake. • Clinically significant (i.e. active) cardiovascular disease e.g. cerebrovascular accidents (= 6 months prior to randomization), myocardial infarction (= 1 year prior to randomization), uncontrolled hypertension while receiving chronic medication, unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhytmia requiring medication. • Serious, non-healing wound, ulcer, or bone fracture. • Serious intercurrent infections (uncontrolled or requiring treatment). • Current or recent (within the 28 days prior to randomization) treatment with another investigational drug or participation in another investigational study. • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to compare the efficacy, as assessed by overall survival (OS), of surgery and neo-adjuvant chemotherapy to surgery alone in patients with liver metastases of colorectal cancer and a high clinical risk score.;Secondary Objective: • To compare progression free survival (PFS) between the 2 arms • To determine quality of life in the two study arms • To determine treatment response on neoadjuvant chemotherapy • To compare morbidity of surgery and resection rate between the 2 arms • To evaluate whether CEA can predict for treatment response, PFS and OS;Primary end point(s): Primary endpoint of the study will be overall survival (OS), calculated from the date of randomization to the date of death from any cause of the patient. Patients still alive at the date of last contact will be censored.;Timepoint(s) of evaluation of this end point: After 126 events. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Progression free survival (PFS) will be defined from the date of randomization to the first event defined as local/distant recurrence or progression or death from any cause.;Timepoint(s) of evaluation of this end point: After 126 events. | — |
Countries
Netherlands
Contacts
Public ContactTrial Bureau
Erasmus MC Cander Institute
Outcome results
None listed